iTeos TherapeuticsITOS
About: ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Employees: 173
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1.88% more ownership
Funds ownership: 93.44% [Q4 2024] → 95.32% (+1.88%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
9% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 44
5% less funds holding
Funds holding: 134 [Q4 2024] → 127 (-7) [Q1 2025]
17% less capital invested
Capital invested by funds: $262M [Q4 2024] → $217M (-$44.8M) [Q1 2025]
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
78% less call options, than puts
Call options by funds: $1.03M | Put options by funds: $4.67M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Piper Sandler Edward Tenthoff | 44%upside $12 | Overweight Maintained | 14 May 2025 |
Wells Fargo Eva Fortea Verdejo | 56%upside $13 | Overweight Maintained | 14 May 2025 |
Leerink Partners Daina Graybosch | 8%upside $9 | Market Perform Downgraded | 14 May 2025 |
JP Morgan Brian Cheng | 4%downside $8 | Neutral Downgraded | 13 May 2025 |
Financial journalist opinion
Based on 3 articles about ITOS published over the past 30 days









